Work

Initial efficacy and biomarker analysis of a phase 1b study targeting IL-1β and PD-1 with chemotherapy in metastatic pancreatic cancer (PanCAN-SR1).

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.e16287

Authors: Paul Eliezer Oberstein, Osama E. Rahma, Nina Beri, Amy C. Stoll-D'Astice, Anne-Marie Duliege, Emily Kawaler, Igor Dolgalev, Gregor Werba, Victoire Cardot-Ruffino, Naïma Böllenrücher, Saloney Nazeer, Matthew Squires, Dafna Bar-Sagi, Brian M. Wolpin, Stephanie Dougan, Diane M. Simeone

Institutions: NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, Dana-Farber Cancer Institute, University of Pennsylvania, Cancer Research And Biostatistics, ChemoCentryx (United States), New York University, Novartis (Switzerland)

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4286299139

Cites:

Cited by: 1

Related to: 10